Pushpa Narayanaswami, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myasthenia Gravis | 13 | 2024 | 199 | 6.440 |
Why?
|
Muscular Dystrophies, Limb-Girdle | 5 | 2021 | 61 | 2.770 |
Why?
|
Neurology | 10 | 2019 | 763 | 2.410 |
Why?
|
Complementary Therapies | 4 | 2015 | 486 | 1.480 |
Why?
|
Neuromuscular Diseases | 4 | 2021 | 248 | 1.450 |
Why?
|
Multiple Sclerosis | 8 | 2019 | 3079 | 1.390 |
Why?
|
Thymectomy | 6 | 2020 | 191 | 1.320 |
Why?
|
Electrodiagnosis | 4 | 2020 | 151 | 1.240 |
Why?
|
Muscular Dystrophies | 3 | 2021 | 393 | 1.200 |
Why?
|
Electromyography | 9 | 2020 | 1379 | 1.130 |
Why?
|
Conflict of Interest | 3 | 2019 | 544 | 1.060 |
Why?
|
Neural Conduction | 8 | 2021 | 440 | 1.040 |
Why?
|
Mycophenolic Acid | 2 | 2024 | 343 | 0.930 |
Why?
|
Radiculopathy | 3 | 2015 | 197 | 0.910 |
Why?
|
Azathioprine | 1 | 2024 | 353 | 0.850 |
Why?
|
Drug Industry | 2 | 2019 | 746 | 0.850 |
Why?
|
Practice Guidelines as Topic | 8 | 2020 | 7279 | 0.830 |
Why?
|
Cannabinoids | 2 | 2014 | 166 | 0.820 |
Why?
|
Immunosuppressive Agents | 6 | 2024 | 4149 | 0.790 |
Why?
|
Guillain-Barre Syndrome | 3 | 2021 | 120 | 0.770 |
Why?
|
Myositis | 1 | 2024 | 251 | 0.760 |
Why?
|
Carpal Tunnel Syndrome | 2 | 2020 | 300 | 0.620 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 685 | 0.620 |
Why?
|
Academies and Institutes | 3 | 2019 | 317 | 0.610 |
Why?
|
Guidelines as Topic | 2 | 2014 | 1405 | 0.600 |
Why?
|
Muscle, Skeletal | 10 | 2021 | 4931 | 0.590 |
Why?
|
Sialorrhea | 1 | 2016 | 25 | 0.570 |
Why?
|
Research Report | 2 | 2016 | 355 | 0.540 |
Why?
|
Diabetic Foot | 1 | 2019 | 355 | 0.530 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2018 | 256 | 0.530 |
Why?
|
Oligonucleotides, Antisense | 1 | 2017 | 433 | 0.520 |
Why?
|
Communicable Diseases | 1 | 2023 | 880 | 0.500 |
Why?
|
Immunization | 1 | 2019 | 1256 | 0.500 |
Why?
|
Consensus | 4 | 2020 | 2959 | 0.500 |
Why?
|
Botulinum Toxins | 1 | 2016 | 191 | 0.490 |
Why?
|
Meningitis | 1 | 2015 | 216 | 0.460 |
Why?
|
Disclosure | 1 | 2019 | 736 | 0.450 |
Why?
|
Myography | 4 | 2021 | 109 | 0.430 |
Why?
|
Comparative Effectiveness Research | 1 | 2018 | 681 | 0.430 |
Why?
|
Career Mobility | 1 | 2014 | 262 | 0.420 |
Why?
|
Reimbursement, Incentive | 1 | 2017 | 540 | 0.410 |
Why?
|
Quality of Life | 4 | 2024 | 12804 | 0.410 |
Why?
|
Evidence-Based Medicine | 4 | 2018 | 3610 | 0.390 |
Why?
|
Electric Impedance | 9 | 2021 | 729 | 0.380 |
Why?
|
Family Health | 1 | 2015 | 1282 | 0.370 |
Why?
|
Glucocorticoids | 1 | 2020 | 2107 | 0.370 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3133 | 0.370 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3240 | 0.360 |
Why?
|
Nervous System Diseases | 2 | 2019 | 1622 | 0.360 |
Why?
|
Disability Evaluation | 1 | 2017 | 1827 | 0.340 |
Why?
|
Humans | 65 | 2024 | 744343 | 0.340 |
Why?
|
Pandemics | 5 | 2023 | 8388 | 0.340 |
Why?
|
Databases, Factual | 3 | 2019 | 7729 | 0.340 |
Why?
|
Physicians | 3 | 2017 | 4567 | 0.330 |
Why?
|
Neurologic Examination | 1 | 2012 | 930 | 0.330 |
Why?
|
Physician-Patient Relations | 2 | 2015 | 3229 | 0.320 |
Why?
|
Career Choice | 1 | 2014 | 744 | 0.320 |
Why?
|
Medicine | 1 | 2016 | 946 | 0.310 |
Why?
|
Physician's Role | 1 | 2015 | 943 | 0.300 |
Why?
|
Prednisone | 2 | 2024 | 1574 | 0.300 |
Why?
|
Vaccination | 1 | 2019 | 3278 | 0.290 |
Why?
|
Information Dissemination | 1 | 2015 | 1099 | 0.290 |
Why?
|
Amyotrophic Lateral Sclerosis | 4 | 2020 | 1414 | 0.280 |
Why?
|
Polyneuropathies | 1 | 2007 | 137 | 0.270 |
Why?
|
Arthritis, Psoriatic | 1 | 2007 | 215 | 0.250 |
Why?
|
Sequence Analysis, DNA | 1 | 2015 | 4803 | 0.240 |
Why?
|
Quality of Health Care | 3 | 2020 | 4371 | 0.240 |
Why?
|
Severity of Illness Index | 4 | 2017 | 15540 | 0.240 |
Why?
|
Complement Inactivating Agents | 1 | 2024 | 50 | 0.230 |
Why?
|
Outpatients | 2 | 2020 | 1486 | 0.220 |
Why?
|
Parkinson Disease | 1 | 2016 | 2775 | 0.210 |
Why?
|
Health Policy | 1 | 2014 | 2661 | 0.210 |
Why?
|
Receptors, Cholinergic | 2 | 2020 | 238 | 0.210 |
Why?
|
Autoimmune Diseases of the Nervous System | 1 | 2003 | 67 | 0.210 |
Why?
|
Research Design | 1 | 2018 | 5987 | 0.200 |
Why?
|
Ulnar Neuropathies | 1 | 2021 | 33 | 0.200 |
Why?
|
Diagnosis, Differential | 4 | 2023 | 12959 | 0.190 |
Why?
|
Reproducibility of Results | 6 | 2018 | 19905 | 0.190 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 7913 | 0.180 |
Why?
|
Quality Improvement | 1 | 2015 | 3749 | 0.180 |
Why?
|
Delivery of Health Care | 2 | 2020 | 5319 | 0.180 |
Why?
|
United States | 12 | 2020 | 69872 | 0.180 |
Why?
|
Arthritis, Rheumatoid | 1 | 2015 | 3712 | 0.170 |
Why?
|
Median Nerve | 1 | 2020 | 129 | 0.170 |
Why?
|
Medicare | 1 | 2017 | 6566 | 0.170 |
Why?
|
Sternotomy | 1 | 2020 | 121 | 0.170 |
Why?
|
Self-Assessment | 1 | 2020 | 390 | 0.160 |
Why?
|
Elbow Joint | 1 | 2021 | 357 | 0.150 |
Why?
|
Referral and Consultation | 2 | 2020 | 3528 | 0.150 |
Why?
|
Muscle Fibers, Skeletal | 2 | 2012 | 555 | 0.150 |
Why?
|
Appointments and Schedules | 1 | 2020 | 417 | 0.140 |
Why?
|
Patient Satisfaction | 1 | 2008 | 3396 | 0.140 |
Why?
|
Foot | 1 | 2019 | 527 | 0.130 |
Why?
|
Parotid Gland | 1 | 2016 | 168 | 0.130 |
Why?
|
Plasma Exchange | 1 | 2016 | 152 | 0.130 |
Why?
|
Oligonucleotides | 1 | 2018 | 572 | 0.130 |
Why?
|
Muscular Atrophy, Spinal | 1 | 2018 | 259 | 0.130 |
Why?
|
Consciousness Disorders | 1 | 2019 | 418 | 0.130 |
Why?
|
Aged, 80 and over | 7 | 2024 | 57776 | 0.120 |
Why?
|
Attitude of Health Personnel | 1 | 2008 | 3843 | 0.120 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 547 | 0.120 |
Why?
|
Methotrexate | 1 | 2020 | 1727 | 0.120 |
Why?
|
Middle Aged | 14 | 2024 | 213383 | 0.120 |
Why?
|
Brain | 1 | 2020 | 26385 | 0.110 |
Why?
|
Telemedicine | 2 | 2020 | 2872 | 0.110 |
Why?
|
Subcutaneous Fat | 2 | 2013 | 391 | 0.110 |
Why?
|
Sensitivity and Specificity | 3 | 2017 | 14722 | 0.110 |
Why?
|
Single-Blind Method | 1 | 2015 | 1590 | 0.100 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2016 | 652 | 0.100 |
Why?
|
Autoantibodies | 1 | 2020 | 2035 | 0.100 |
Why?
|
Male | 17 | 2024 | 350118 | 0.100 |
Why?
|
Female | 17 | 2021 | 380194 | 0.100 |
Why?
|
Meta-Analysis as Topic | 1 | 2016 | 1344 | 0.100 |
Why?
|
Muscle Contraction | 1 | 2016 | 1240 | 0.100 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1439 | 0.100 |
Why?
|
Mutation | 1 | 2015 | 29786 | 0.100 |
Why?
|
Action Potentials | 2 | 2009 | 1806 | 0.100 |
Why?
|
Goals | 1 | 2016 | 706 | 0.090 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2029 | 0.090 |
Why?
|
Video Recording | 1 | 2015 | 949 | 0.090 |
Why?
|
Adult | 11 | 2024 | 214055 | 0.090 |
Why?
|
Disease Management | 1 | 2020 | 2459 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2020 | 1831 | 0.090 |
Why?
|
Sciatic Nerve | 2 | 2010 | 607 | 0.090 |
Why?
|
Aged | 11 | 2020 | 163280 | 0.080 |
Why?
|
Research | 1 | 2017 | 1999 | 0.080 |
Why?
|
Psychometrics | 1 | 2018 | 3002 | 0.080 |
Why?
|
Treatment Outcome | 4 | 2021 | 63114 | 0.080 |
Why?
|
Pregnancy | 3 | 2021 | 29144 | 0.080 |
Why?
|
Nerve Fibers | 1 | 2012 | 687 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8642 | 0.080 |
Why?
|
Cell Size | 1 | 2009 | 643 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2016 | 6365 | 0.070 |
Why?
|
Disease Progression | 3 | 2020 | 13284 | 0.070 |
Why?
|
Prospective Studies | 2 | 2024 | 53288 | 0.070 |
Why?
|
Probability | 1 | 2012 | 2505 | 0.070 |
Why?
|
Adrenal Cortex Hormones | 1 | 2015 | 1855 | 0.070 |
Why?
|
Societies, Medical | 2 | 2018 | 3743 | 0.070 |
Why?
|
Adolescent | 5 | 2024 | 85781 | 0.070 |
Why?
|
Retrospective Studies | 4 | 2019 | 77449 | 0.070 |
Why?
|
Lower Extremity | 1 | 2013 | 1158 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9239 | 0.070 |
Why?
|
Young Adult | 6 | 2015 | 56430 | 0.060 |
Why?
|
Hereditary Sensory and Autonomic Neuropathies | 1 | 2004 | 40 | 0.060 |
Why?
|
Health Expenditures | 1 | 2017 | 2348 | 0.060 |
Why?
|
Charcot-Marie-Tooth Disease | 1 | 2004 | 94 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2020 | 13989 | 0.060 |
Why?
|
Child | 3 | 2018 | 77709 | 0.060 |
Why?
|
Sex Characteristics | 1 | 2013 | 2585 | 0.060 |
Why?
|
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2003 | 31 | 0.050 |
Why?
|
Aging | 2 | 2013 | 8664 | 0.050 |
Why?
|
Education, Medical, Graduate | 1 | 2014 | 2291 | 0.050 |
Why?
|
Double-Blind Method | 1 | 2016 | 12026 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2716 | 0.050 |
Why?
|
Ulnar Nerve | 1 | 2021 | 106 | 0.050 |
Why?
|
Health Care Costs | 1 | 2015 | 3209 | 0.050 |
Why?
|
Elbow | 1 | 2021 | 138 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 9959 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5751 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 35421 | 0.050 |
Why?
|
Immunocompetence | 1 | 2021 | 137 | 0.050 |
Why?
|
Time Factors | 2 | 2020 | 40075 | 0.050 |
Why?
|
Vaccines, Inactivated | 1 | 2021 | 184 | 0.050 |
Why?
|
Decontamination | 1 | 2020 | 69 | 0.050 |
Why?
|
Vaccines, Attenuated | 1 | 2021 | 342 | 0.040 |
Why?
|
Equipment Contamination | 1 | 2020 | 185 | 0.040 |
Why?
|
Health Surveys | 1 | 2008 | 4037 | 0.040 |
Why?
|
Diagnostic Self Evaluation | 1 | 2020 | 230 | 0.040 |
Why?
|
Masks | 1 | 2020 | 197 | 0.040 |
Why?
|
Bipolar Disorder | 1 | 2015 | 5027 | 0.040 |
Why?
|
Vital Capacity | 1 | 2020 | 925 | 0.040 |
Why?
|
Hand Strength | 1 | 2020 | 448 | 0.040 |
Why?
|
Sample Size | 1 | 2020 | 845 | 0.040 |
Why?
|
Rats, Wistar | 2 | 2010 | 1901 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2021 | 847 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2065 | 0.030 |
Why?
|
Ultrasonography | 2 | 2021 | 5985 | 0.030 |
Why?
|
Muscle Strength Dynamometer | 1 | 2013 | 43 | 0.030 |
Why?
|
Mental Disorders | 1 | 2013 | 6600 | 0.030 |
Why?
|
Off-Label Use | 1 | 2015 | 169 | 0.030 |
Why?
|
Triage | 1 | 2020 | 976 | 0.030 |
Why?
|
Infection Control | 1 | 2020 | 966 | 0.030 |
Why?
|
Lumbosacral Region | 1 | 2013 | 310 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1580 | 0.020 |
Why?
|
Algorithms | 1 | 2012 | 13881 | 0.020 |
Why?
|
Affective Symptoms | 1 | 2013 | 407 | 0.020 |
Why?
|
Evoked Potentials, Motor | 1 | 2013 | 454 | 0.020 |
Why?
|
Needles | 1 | 2013 | 449 | 0.020 |
Why?
|
Muscle Denervation | 1 | 2010 | 57 | 0.020 |
Why?
|
Electrodes | 1 | 2012 | 619 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2018 | 1660 | 0.020 |
Why?
|
Nerve Crush | 1 | 2009 | 78 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2020 | 2708 | 0.020 |
Why?
|
Electric Conductivity | 1 | 2009 | 411 | 0.020 |
Why?
|
Demography | 1 | 2013 | 1656 | 0.020 |
Why?
|
Caregivers | 1 | 2020 | 2094 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2013 | 975 | 0.020 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 1953 | 0.020 |
Why?
|
Anisotropy | 1 | 2010 | 1265 | 0.020 |
Why?
|
Electric Stimulation | 1 | 2010 | 1767 | 0.020 |
Why?
|
Mass Screening | 1 | 2020 | 5255 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2886 | 0.010 |
Why?
|
Pregnancy Complications | 1 | 2018 | 2861 | 0.010 |
Why?
|
Insurance Coverage | 1 | 2015 | 1901 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2013 | 6038 | 0.010 |
Why?
|
Rats | 2 | 2010 | 24260 | 0.010 |
Why?
|
Immunotherapy | 1 | 2018 | 4445 | 0.010 |
Why?
|
Linear Models | 1 | 2009 | 5952 | 0.010 |
Why?
|
Survival Rate | 1 | 2012 | 12788 | 0.010 |
Why?
|
Depression | 1 | 2013 | 7766 | 0.010 |
Why?
|
Animals | 2 | 2010 | 168757 | 0.000 |
Why?
|